SEMA3F and breast carcinoma: Reduced levels of RORα and SEMA3F have been found to be linked to poor clinical outcomes in human breast cancer cells; however, RORα activation suppresses aggressive phenotypes, tumor invasion, and growth of breast cancer cells in vivo [88].